not sure what outcome you expect from this exercise.
CHM is a thinly capitalised micro cap - if you are after best practice for corporate governance and compliance, suggest you invest in a banking stock.
Sure - SP is under pressure, and there have been a few wobbles - but we are also making great strides in the clinic. With CHM CDH17 there may be a number of world firsts:
- proven efficacy against GI cancer targeting CDH17 antigen
- CART with durable persistence that works against solid tumours
- very long patent life
this could make the company and its assets very, very valuable to big pharma.
not sure what outcome you expect from this exercise. CHM is a...
Add to My Watchlist
What is My Watchlist?
